Marta Milà‐Alomà

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

Andréa Lessa Benedet, Marta Milà‐Alomà, Agathe Vrillon et al. · JAMA Neurology · 2021 · 566 citations · Full text

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s <i>continuum</i> when only subtle changes in Aβ pathology are detected

Marc Suárez‐Calvet, Thomas K. Karikari, Nicholas J. Ashton et al. · EMBO Molecular Medicine · 2020 · 392 citations · Full text

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Marta Milà‐Alomà, Nicholas J. Ashton, Mahnaz Shekari et al. · Nature Medicine · 2022 · 341 citations · Full text

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i>

Marta Milà‐Alomà, Gemma Salvadó, Juan Domingo Gispert et al. · Alzheimer s & Dementia · 2020 · 245 citations · Full text

Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays

Nicholas J. Ashton, Albert Puig‐Pijoan, Marta Milà‐Alomà et al. · Alzheimer s & Dementia · 2022 · 209 citations · Full text